Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01281592 · ClinicalTrials.gov registry record · Phase 1
A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours
A Phase 1 study, sponsored by Aptose Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT01281592 is a Phase 1 study that has completed, run by Aptose Biosciences. The registered enrollment target is 36 participants.
The verdict
NCT01281592, a Phase 1 study, has completed, sponsored by Aptose Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
This is an open-label, phase 1 study to determine the maximum tolerated dose (MTD) or appropriate target dose if MTD not reached to identify the recommended phase 2 dose of LOR-253 HCl in patients with advanced or metastatic solid tumours.
Interventions
- DRUG LOR-253 HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2011-01 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01281592
The ClinicalTrials.gov registry entry for NCT01281592 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aptose Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LOR-253 HCl is the first listed.
NCT01281592 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01281592 about?
NCT01281592 is a clinical study titled "A Study of LOR-253 HCl in Patients With Advanced or Metastatic Solid Tumours". This is an open-label, phase 1 study to determine the maximum tolerated dose (MTD) or appropriate target dose if MTD not reached to identify the recommended phase 2 dose of LOR-253 HCl in patients with advanced or metastatic solid tumours.
What is the current status of trial NCT01281592?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2011-01. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01281592?
The interventions under investigation include: LOR-253 HCl (DRUG).
Who is sponsoring clinical trial NCT01281592?
This trial is sponsored by Aptose Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.